So it's really interesting how this field is evolving because the omics, as you put it, whether it's proteomics, and now we're learning also about the epigenome and what brings us to the potential that this class of drugs would have an impact on health span in all people, not just those who are obese
The peer-reviewed findings will be presented on Saturday (June 13) at ENDO 2026, the Endocrine Society's annual meeting
others using it for specific detox routines build effects over 4-12 weeks under practitioner guidance
8 Another 2023 meta-analysis among 93 studies comparing GLP-1 RAs to placebo, insulin, or oral antidiabetic medicine found GLP-1RA use was associated with increased risk of both early and late-stage DR, although these results barely reached statistical significance with 95% confidence intervals of 1.01 to 1.68 and 1.01 to 1.66, respectively
Upadhyaya et al., 2008
doi: 10.1096/fj.10-158105 66 ZolotukhinS